Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) Net Income towards Common Stockholders (2021 - 2026)

Envoy Medical's Net Income towards Common Stockholders history spans 5 years, with the latest figure at -$5.7 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 8.58% to -$5.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$28.1 million, a 5.84% decrease, with the full-year FY2025 number at -$28.7 million, down 2.46% from a year prior.
  • Net Income towards Common Stockholders hit -$5.7 million in Q1 2026 for Envoy Medical, up from -$7.7 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for COCH hit a ceiling of $10.6 million in Q2 2022 and a floor of -$13.3 million in Q1 2023.
  • Historically, Net Income towards Common Stockholders has averaged -$5.5 million across 5 years, with a median of -$6.9 million in 2025.
  • The widest YoY moves for Net Income towards Common Stockholders: up 204.56% in 2023, down 631.76% in 2023.
  • Tracing COCH's Net Income towards Common Stockholders over 5 years: stood at -$11.5 million in 2022, then soared by 45.6% to -$6.2 million in 2023, then fell by 23.09% to -$7.7 million in 2024, then dropped by 0.66% to -$7.7 million in 2025, then grew by 26.32% to -$5.7 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for COCH at -$5.7 million in Q1 2026, -$7.7 million in Q4 2025, and -$7.7 million in Q3 2025.